Genelux (GNLX) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genelux in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GNLX shares.
View GNLX analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 12-month target prices for Genelux's shares. Their GNLX share price forecasts range from $10.00 to $40.00. On average, they expect the company's share price to reach $25.00 in the next twelve months. This suggests that the stock has a possible downside of 7.0%.
View analysts price targets for GNLX or view top-rated stocks among Wall Street analysts.

Genelux's stock was trading at $6.01 on January 1st, 2023. Since then, GNLX stock has increased by 347.3% and is now trading at $26.88.
View the best growth stocks for 2023 here.

Genelux saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 166,900 shares, an increase of 8.6% from the August 15th total of 153,700 shares. Based on an average daily trading volume, of 96,300 shares, the short-interest ratio is currently 1.7 days. Approximately 0.9% of the shares of the company are short sold.
View Genelux's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our GNLX earnings forecast.

Genelux Co. (NASDAQ:GNLX) issued its quarterly earnings results on Monday, August, 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.09.

(GNLX) raised $16 million in an initial public offering on Thursday, January 26th 2023. The company issued 2,500,000 shares at $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets acted as the underwriters for the IPO.

Genelux trades on the NASDAQ under the ticker symbol "GNLX."

Genelux's lock-up period expired on Tuesday, July 25th. Genelux had issued 2,500,000 shares in its initial public offering on January 26th. The total size of the offering was $15,000,000 based on an initial share price of $6.00. Since the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Genelux's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.55%), Geode Capital Management LLC (0.25%), State Street Corp (0.19%), Northern Trust Corp (0.13%), Hohimer Wealth Management LLC (0.09%) and Charles Schwab Investment Management Inc. (0.07%). Insiders that own company stock include Aladar Szalay, Caroline Jewett, Doug Samuelson, John Thomas, John W Smither, Joseph Cappello, Qian Zhang, Sean Ryder, Thomas Zindrick and Yong Yu.
View institutional ownership trends.

Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GNLX stock can currently be purchased for approximately $26.88.

Genelux (NASDAQ:GNLX) has a market capitalization of $663.13 million and generates $11.07 million in revenue each year.

Genelux's mailing address is 2625 Townsgate Road Suite 230, Westlake Village CA, 91361. The official website for the company is www.genelux.com. The company can be reached via phone at 805-267-9889 or via email at genelux@allelecomms.com.